---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-104154"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:22:53.846113+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# INmune Bio Q3 net loss $6.5M; appoints new CEO, CFO; INKmune trial meets primary endpoint

## Summary
- Net loss narrowed to $6.5M from $12.1M YoY; R&D spend cut to $4.9M; cash $27.7M.
- David Moss appointed President & CEO replacing Dr. RJ Tesi; Cory Ellspermann named CFO.
- XPro1595 Phase 2 MINDFuL results manuscript submitted; End-of-Phase 2 meeting with FDA expected Q1 2026.
- INKmune CARE-PC trial met primary endpoint and 2 of 3 secondary endpoints; trial closed to recruitment.
- CORDStrom commercial pilot runs complete; MAA submission on track for mid-2026.

## SEC filing metadata
- accession: 0001213900-25-104154
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025104154/0001213900-25-104154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025104154/ea0263196-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-104154
- JSON: https://secwatch.observer/filing/0001213900-25-104154.json
- Plain text: https://secwatch.observer/filing/0001213900-25-104154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.